摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-噻吩基)丁酸 | 4653-11-6

中文名称
4-(2-噻吩基)丁酸
中文别名
4-(2-噻嗯基)丁酸;2-噻吩丁酸;4-(2-噻吩)丁酸;4-2-噻吩丁酸;4-(2-噻嗯基)丁酸
英文名称
2-thiophenebutyric acid
英文别名
4-(2-Thienyl)butyric acid;4-(thiophen-2-yl)butanoic acid;4-thiophen-2-ylbutanoic acid
4-(2-噻吩基)丁酸化学式
CAS
4653-11-6
化学式
C8H10O2S
mdl
MFCD00005463
分子量
170.232
InChiKey
VYTXLSQVYGNWLV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    13.5-15 °C
  • 沸点:
    122°C 0,3mm
  • 密度:
    1.169 g/mL at 25 °C(lit.)
  • 闪点:
    >230 °F
  • 稳定性/保质期:
    在常温常压下保持稳定

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    11
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    65.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 安全说明:
    S26,S37/39
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2934999090
  • 危险标志:
    GHS07
  • 危险性描述:
    H315,H319,H335
  • 危险性防范说明:
    P261,P305 + P351 + P338
  • 包装等级:
    III
  • 危险类别:
    8
  • 危险品运输编号:
    3265
  • 储存条件:
    请将药品存放在避光、通风干燥的地方,并密封保存。

SDS

SDS:1525d563f15e8c91e472f80eb6b50851
查看
Name: 4-(2-Thienyl)butyric Acid 98% Material Safety Data Sheet
Synonym: 2-Thiophenebutyric Acid
CAS: 4653-11-6
Section 1 - Chemical Product MSDS Name:4-(2-Thienyl)butyric Acid 98% Material Safety Data Sheet
Synonym:2-Thiophenebutyric Acid

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
4653-11-6 4-(2-Thienyl)butyric Acid 98% 225-090-0
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Containers may explode in the heat of a fire. Vapors may be heavier than air.
They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray to cool fire-exposed containers. Use agent most appropriate to extinguish fire.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Exposure Limits CAS# 4653-11-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear slight brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 112 deg C (> 233.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: 1.1690g/cm3
Molecular Formula: C8H10O2S
Molecular Weight: 170.23

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, sulfur oxides (SOx), including sulfur oxide and sulfur dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4653-11-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(2-Thienyl)butyric Acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 4653-11-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4653-11-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4653-11-6 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

医药中间体

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
    申请人:Florjancic S. Alan
    公开号:US20080058335A1
    公开(公告)日:2008-03-06
    The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    本发明涉及式(I)的化合物,或药用盐、前药、前药的盐或其组合物, 其中R 1 ,R 2 ,R 3 和L 1 在规范中定义,包含这种化合物的组合物,以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物,或药用盐、前药、前药的盐或其组合物, 其中R 1a ,R 2a 和(Rx)n如规范中定义,包含这种化合物的组合物,以及使用这种化合物和组合物治疗疾病和疾病的方法。
  • Design and synthesis of a library of tertiary amides: Evaluation as mimetics of the melanocortins’ active core
    作者:Felikss Mutulis、Jana Kreicberga、Sviatlana Yahorava、Ilze Mutule、Larisa Borisova-Jan、Aleh Yahorau、Ruta Muceniece、Sandra Azena、Santa Veiksina、Ramona Petrovska
    DOI:10.1016/j.bmc.2007.06.003
    日期:2007.9.1
    acceptable results. According to this approach an efficient formation of Schiff bases was achieved in the presence of TiCl(4). Substances were isolated by reversed phase chromatography; in some cases isomers were additionally separated by chiral chromatography on Chirobiotic T. When tested on human recombinant melanocortin receptors all the tertiary amides showed some binding affinities; for the highest affinity
    在固相上制备了201种叔酰胺。将二胺偶联到活化的羧化王聚合物上,并使所得的聚合物取代的苄氧羰基保护的二胺与原甲酸三甲酯中的醛或酮反应,得到树脂连接的席夫碱。然后将偶联的树脂通过在4%的乙酸/原甲酸三甲酯中的氰基硼氢化钠还原为仲胺,然后在PyBroP和二异丙基乙胺的存在下用羧酸酰化。在清除剂(主要是1,2-乙二硫醇)存在下,通过三氟乙酸从树脂上裂解叔酰胺。当制备吲哚衍生物时,与连接体片段发生平行烷基化,得到2-(4-羟基苄基)-吲哚的衍生物作为副产物。在上述方法未给出可接受的结果的情况下,标题化合物的溶液合成或液相/固相混合制备被证明是有利的。根据这种方法,在TiCl(4)存在的情况下实现了席夫碱的有效形成。物质经反相色谱分离。在某些情况下,还可以通过在Chirobiotic T上进行手性色谱分离来分离异构体。在人重组黑皮质素受体上进行测试时,所有叔酰胺都表现出一定的结合亲和力。对于具有最高
  • Reaction Discovery by Using a Sandwich Immunoassay
    作者:Julia Quinton、Sergii Kolodych、Manon Chaumonet、Valentina Bevilacqua、Marie-Claire Nevers、Hervé Volland、Sandra Gabillet、Pierre Thuéry、Christophe Créminon、Frédéric Taran
    DOI:10.1002/anie.201201451
    日期:2012.6.18
    Mmm, a reaction sandwich…︁ Using an immunoassay‐based technique able to monitor any kind of cross‐coupling reaction, a systematic and rapid evaluation of a large panel of random reactions was carried out. This approach led to the discovery of two new copper‐promoted reactions: a desulfurization reaction of thioureas leading to isoureas and a cyclization reaction leading to thiazole derivatives from
    嗯,反应夹心……︁使用基于免疫分析的技术能够监测任何种类的交叉偶联反应,对大量随机反应进行了系统,快速的评估。这种方法导致发现了两个新的铜促进的反应:硫脲的脱硫反应导致异脲,环化反应导致炔烃和N-羟基硫脲的噻唑衍生物。
  • Ruthenium(II)-Catalyzed Enantioselective γ-Lactams Formation by Intramolecular C–H Amidation of 1,4,2-Dioxazol-5-ones
    作者:Qi Xing、Chun-Ming Chan、Yiu-Wai Yeung、Wing-Yiu Yu
    DOI:10.1021/jacs.9b00535
    日期:2019.3.6
    C-H insertion. By employing chiral diphenylethylene diamine (dpen) as ligands bearing electron-withdrawing arylsulfonyl substituents, the reactions occur with remarkable chemo- and enantioselectivities; the competing Curtius-type rearrangement was largely suppressed. Enantioselective nitrene insertion to allylic/propargylic C-H bonds was also achieved with remarkable tolerance to the CC and CC bonds
    我们报告了 Ru 催化的 1,4,2-二恶唑-5-酮的对映选择性环化,通过分子内羰基硝基 CH 插入以高达 97% 的产率和 98% 的 ee 提供 γ-内酰胺。通过使用手性二苯基乙二胺 (dpen) 作为带有吸电子芳基磺酰基取代基的配体,反应发生时具有显着的化学和对映选择性;竞争性的 Curtius 型重排在很大程度上被抑制了。对映选择性氮烯插入烯丙基/炔丙基 CH 键也实现了对 C=C 和 C≡C 键的显着耐受性。
  • N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
    申请人:——
    公开号:US20020165241A1
    公开(公告)日:2002-11-07
    Compounds represented by Formula (I): 1 or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
    由化学式(I)表示的化合物及其药学上可接受的盐,可作为NMDA NR2B拮抗剂,用于缓解疼痛。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
hnmr
mass
cnmr
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

香薷二醇 顺式-1-(2-呋喃基)-1-戊烯 顺-1,2-二氰基-1,2-双(2,4,5-三甲基-3-噻吩基)乙烯 顺-1,2-(2-噻嗯基)二乙烯 雷尼替丁-N,S-二氧化物 雷尼替丁-N-氧化物 西拉诺德 螺[环氧乙烷-2,3'-吡咯并[1,2-a]吡嗪] 萘并[2,1,8-def]喹啉 苯硫基溴化镁 苯甲酸,2-[[[7-[[(3.β.)-3-羟基-28-羰基羽扇-20(29)-烯-28-基]amino]庚基]氨基]羰基] 苍术素 缩水甘油糠醚 紫苏烯 糠醛肟 糠醇-d2 糠醇 糠基硫醇-d2 糠基硫醇 糠基甲基硫醚 糠基氯 糠基氨基甲酸异丙酯 糠基丙基醚 糠基丙基二硫醚 糠基3-巯基-2-甲基丙酸酯 糠基-异戊基醚 糠基-异丁基醚 糠基 2-甲基-3-呋喃基二硫醚 磷杂茂 硫酸异丙基糠酯 硫代磷酸O-糠基O-甲基S-(2-丙炔基)酯 硫代磷酸O-乙基O-糠基S-(2-丙炔基)酯 硫代甲酸S-糠酯 硫代噻吩甲酰基三氟丙酮 硫代乙酸糠酯 硫代丙酸糠酯 硅烷,三(1-甲基乙基)[(3-甲基-2-呋喃基)氧代]- 硅烷,(1,1-二甲基乙基)(2-呋喃基甲氧基)二甲基- 砷杂苯 甲酸糠酯 甲氧亚胺基呋喃乙酸铵盐 甲基糠基醚 甲基糠基二硫 甲基呋喃-2-基甲基氨基甲酸酯 甲基丙烯酸糠酯 甲基5-(羟基甲基)-2-呋喃甲亚氨酸酯 甲基(2Z)-3-甲基-2-(甲基亚胺)-4-氧代-3,4-二氢-2H-1,3-噻嗪-6-羧酸酯 甲基(2Z)-3-氨基-2-(甲基亚胺)-4-氧代-3,4-二氢-2H-1,3-噻嗪-6-羧酸酯 甲基(2Z)-3-异丙基-2-(异丙基亚胺)-4-氧代-3,4-二氢-2H-1,3-噻嗪-6-羧酸酯 甲基(2-甲基-3-呋喃基)二硫